Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025BloodOpen Access

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLorenzo FalchiASAnna SuredaSLSirpa Leppä

Discussion

Loading...

Member takes

Overview

Phase 1b/2 trial reveals 96% overall response rate in relapsed follicular lymphoma, indicating significant clinical benefit.

Key Points

  • Epcoritamab plus R2 achieved an impressive overall response rate of 96% among patients with relapsed or refractory follicular lymphoma.
  • Complete response rate reached 88%, with high-risk patients showing notable rates of 90% for primary refractory cases.
  • Analysis showed 86% minimal residual disease negativity based on clonoSEQ assay, reaffirming treatment effectiveness.
  • Common treatment-emergent adverse events included neutropenia and COVID-19, all manageable without discontinuation.

Cite This Study

Falchi et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478bf41https://doi.org/10.1182/blood.2025029909
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  2. 2Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 1 citations
  3. 3Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  4. 4Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study2025
  5. 5Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety2025